- Oxygen Biotherapeutics (OXBT) leaps 19% premarket.
- The company says aggregated results from 14 clinical trials show "levosimendan was associated with reduced mortality and other adverse outcomes including heart attacks during and after operation in patients with reduced heart function undergoing heart surgery."
- The findings were published in the Journal of Cardiothoracic and Vascular Anesthesia. (PR)
- OXBT is set to acquire the U.S. commercialization and development rights to levosimendan from privately held Phyxius Pharma. More on this deal here.
Oxygen Biotherapeutics rises as meta-analysis highlights levosimendan benefits
From other sites
at MarketWatch.com (Sep 15, 2014)
at CNBC.com (Jun 25, 2014)
at CNBC.com (Mar 31, 2014)
at CNBC.com (Mar 17, 2014)
at MarketWatch.com (Mar 4, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs